---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-000729"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:22:56.344053+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cyclacel places UK subsidiary into CVL; to buy plogosertib, sell fadraciclib

## Summary
- UK subsidiary Cyclacel Ltd entered creditors voluntary liquidation; joint liquidators appointed.
- Company plans to purchase plogosertib from liquidators for new oral formulation development.
- Fadraciclib program will be marketed for sale by liquidators and removed from company assets.
- Deconsolidation expected to increase stockholders' equity by approximately $5.6M in Q1 2025.

## SEC filing metadata
- accession: 0001829126-25-000729
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000182912625000729/0001829126-25-000729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000182912625000729/cyclacelpharma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-000729
- JSON: https://secwatch.observer/filing/0001829126-25-000729.json
- Plain text: https://secwatch.observer/filing/0001829126-25-000729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.